|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-12-14
|
|
pubmed:abstractText |
CHOP regimen is the standard treatment for patients with diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody, is effective in treating diffuse large B-cell lymphoma. This study was conducted to compare the efficacy of rituximab plus CHOP and CHOP alone on newly diagnosed patients with diffuse large B-cell lymphoma, and analyze their toxicities.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1000-467X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1498-502
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16351800-Adolescent,
pubmed-meshheading:16351800-Adult,
pubmed-meshheading:16351800-Antibodies, Monoclonal,
pubmed-meshheading:16351800-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16351800-Antigens, CD20,
pubmed-meshheading:16351800-Antineoplastic Agents,
pubmed-meshheading:16351800-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16351800-Cyclophosphamide,
pubmed-meshheading:16351800-Doxorubicin,
pubmed-meshheading:16351800-Female,
pubmed-meshheading:16351800-Humans,
pubmed-meshheading:16351800-Leukopenia,
pubmed-meshheading:16351800-Lymphoma, B-Cell,
pubmed-meshheading:16351800-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:16351800-Male,
pubmed-meshheading:16351800-Prednisone,
pubmed-meshheading:16351800-Prospective Studies,
pubmed-meshheading:16351800-Remission Induction,
pubmed-meshheading:16351800-Survival Rate,
pubmed-meshheading:16351800-Vincristine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
[Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
|
|
pubmed:affiliation |
Department of Medicine, Harbin Institute of Hematology and Oncology, Harbin, Heilongjiang 150010, P. R. China. hollywu2001@yahoo.com.cn
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|
